Effectiveness of Sublingual Immunotherapy for Dust Mite Allergy

Introduction to SLIT Efficacy

The American Academy of Allergy, Asthma, and Immunology recommends sublingual immunotherapy (SLIT) as an effective treatment for dust mite allergy in children with allergic rhinitis and asthma, although it is considered investigational in the United States due to the lack of an FDA-approved formulation 1
SLIT has been shown to be effective for house dust mite allergies in both adults and children, with evidence of clinical efficacy in the form of improved symptom scores and reduced medication use, as supported by the European Academy of Allergy and Clinical Immunology 2, 3

The American College of Allergy, Asthma, and Immunology suggests that treatment should begin at least 8 weeks before expected allergen exposure periods for optimal results 2
Approximately 35% of randomized, double-blind, placebo-controlled studies did not demonstrate efficacy in either symptom or medication parameters during the first year of treatment, highlighting the need for ongoing assessment and potential dose adjustment, as recommended by the American Academy of Allergy, Asthma, and Immunology 2

SLIT appears to be safe even at very high doses (up to 500 times the usual monthly subcutaneous dose), with a favorable safety profile in young children, as confirmed by the European Academy of Allergy and Clinical Immunology 2
Common side effects include gastrointestinal and oral reactions, but these are generally mild, according to the American Academy of Allergy, Asthma, and Immunology 3
While rare, there have been case reports of anaphylaxis with SLIT, though no SLIT-related fatalities have been reported, as noted by the American College of Allergy, Asthma, and Immunology 2

SLIT could be considered as an adjunctive treatment to pharmacotherapy in children >5 years old with rhinitis and mild to moderate asthma (FEV1 >80%), as suggested by the American Thoracic Society 6
For a 5-year-old with elevated IgE to dust mites, SLIT may be particularly appropriate given its favorable safety profile in young children, as recommended by the European Academy of Allergy and Clinical Immunology 2

While SLIT can provide sustained benefit, complete permanent immunity to dust mites is not guaranteed, as noted by the American Academy of Allergy, Asthma, and Immunology 4
Some studies suggest SLIT may have persistent benefits after conclusion of therapy, similar to what has been observed with other allergens, according to the European Academy of Allergy and Clinical Immunology 5